Menlo Therapeutics

General Information

We are a late‑stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. There are currently no therapies approved in the United States that are primarily intended to reduce the pruritus associated with these conditions. We are concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. There are currently no drugs specifically approved for refractory chronic cough in the United States. These indications each represent a significant patient need. We believe that serlopitant, a highly selective, once‑daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK1‑R, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms.

Employees: 32
Founded: 2011
Contact Information
Address 200 Cardinal Way, 2nd Floor, Redwood City, CA 94063 US
Phone Number (650) 486-1416
Web Address
View Prospectus: Menlo Therapeutics
Financial Information
Market Cap $372.8mil
Revenues $2.25 mil (last 12 months)
Net Income $-24.6 mil (last 12 months)
IPO Profile
Symbol MNLO
Exchange NASDAQ
Shares (millions): 7.0
Price range $17.00 - $17.00
Est. $ Volume $119.0 mil
Manager / Joint Managers Jefferies/ Piper Jaffray/ Guggenheim Securities
CO-Managers JMP Securities
Expected To Trade: 1/25/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change